NCT01392521 - Phase Ib Study of PI3(Phosphoinositol 3)-Kinase Inhibitor Copanlisib With MEK (Mitogen-activated Protein Kinase) Inhibitor Refametinib (BAY86-9766) in Patients With Advanced Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

February 28, 2014

Study Completion Date

April 30, 2014

Conditions

Neoplasms

Interventions

DRUG

Copanlisib + Refametinib (BAY86-9766)

Copanlisib will be administered as an IV infusion weekly for 3 weeks in combination with Refametinib (BAY86-9766) at varying dose levels. Refametinib (BAY86-9766) is administered orally twice a day starting at Day 4 of Cycle 1.

DRUG

Copanlisib + Refametinib (BAY86-9766)

Copanlisib will be administered as an IV infusion weekly in combination with Refametinib (BAY86-9766) at varying dose levels. Refametinib (BAY86-9766) is administered orally twice a day starting at Day 6 of Cycle 1 on a 4 day on, 3 day off schedule.

Trial Locations (8)

29605

Greenville

75702

Tyler

77030

Houston

79106

Freiburg im Breisgau

85260

Scottsdale

89169

Las Vegas

98684

Vancouver

3015 CE

Rotterdam